Trusted Resource for Clinical Trials, Protocols & Progress
In bioavailability and bioequivalence (BA/BE) studies, analytical method validation is the cornerstone for generating reliable pharmacokinetic data. But beyond executing validation experiments, what truly determines regulatory success is the quality of documentation and reporting. Without comprehensive records, your method — no matter how robust — may fail to meet regulatory scrutiny.
Click to read the full article.
In bioavailability and bioequivalence (BA/BE) studies, demonstrating therapeutic equivalence between a generic and a reference drug is a regulatory cornerstone. Among various statistical tools, the 90% confidence interval (CI) rule is the universally accepted method for assessing bioequivalence. Regulatory bodies such as the FDA, EMA, and CDSCO require that the 90% CI of the pharmacokinetic parameter ratios—such as Cmax and AUC—fall within a defined equivalence margin to be deemed bioequivalent.
Click to read the full article.
Intrasubject variability is a critical factor in the design, analysis, and regulatory acceptance of bioavailability and bioequivalence (BA/BE) studies. High variability can lead to study failures even when two formulations are pharmacokinetically similar. To quantify this variability, the coefficient of variation (CV%) is used — a metric that directly impacts sample size calculations, confidence interval width, and bioequivalence conclusions.
Click to read the full article.
Bioequivalence (BE) studies rely on statistical comparison of pharmacokinetic parameters like Cmax and AUC between test and reference products. However, the presence of outliers—individual data points that significantly deviate from the expected distribution—can distort results, widen confidence intervals, and ultimately lead to failed bioequivalence even when products are therapeutically equivalent. Proper detection and handling of outliers is essential for regulatory compliance and accurate data interpretation.
Click to read the full article.
Replicate designs in bioequivalence (BE) studies are increasingly used, especially for highly variable drugs (HVDs), where conventional two-period crossover studies may not provide conclusive results. These designs involve administering the same formulation (test or reference) more than once to the same subject, allowing estimation of intrasubject variability and subject-by-formulation interactions.
Click to read the full article.
Highly Variable Drug Products (HVDs) present a significant challenge in designing and analyzing bioequivalence (BE) studies. According to FDA and EMA definitions, a drug is considered highly variable if its within-subject coefficient of variation (CV%) is greater than 30% for key pharmacokinetic parameters like Cmax or AUC.
Click to read the full article.
Bioequivalence (BE) assessments rely on comparing key pharmacokinetic parameters like AUC (Area Under the Curve) and Cmax (maximum plasma concentration) between a test and reference formulation. The default regulatory acceptance limits for the 90% confidence interval (CI) of the geometric mean ratio (GMR) of these parameters is 80.00% to 125.00%. These limits ensure that any pharmacokinetic differences are not clinically meaningful.
Click to read the full article.
In the context of bioavailability and bioequivalence (BA/BE) studies, statistical analysis is essential for evaluating whether the test product is equivalent to the reference formulation. One of the most commonly used tools in this process is Analysis of Variance (ANOVA). ANOVA helps identify and isolate the impact of various sources of variability — such as treatment, period, and sequence effects — on key pharmacokinetic parameters like Cmax and AUC.
Click to read the full article.
Accurate sample size estimation is one of the most critical components in the design of a bioavailability and bioequivalence (BA/BE) study. An underpowered study may fail to demonstrate bioequivalence even if it truly exists, while an oversized study wastes resources and raises ethical concerns. Regulatory agencies like the FDA and EMA expect sponsors to justify sample size with respect to study objectives, variability, and statistical power.
Click to read the full article.
The Two One-Sided Tests (TOST) procedure is the gold standard statistical approach used in bioavailability and bioequivalence (BA/BE) studies to determine if two drug products are equivalent in terms of their pharmacokinetic profiles. Rather than testing for a difference, TOST tests for equivalence — an essential distinction in regulatory science. It evaluates whether the 90% confidence interval (CI) for the geometric mean ratio (GMR) of key pharmacokinetic parameters, such as Cmax and AUC, falls entirely within predefined bioequivalence limits (typically 80.00% to 125.00%).
Click to read the full article.
